Subscribe to the BioNews newsletter for free

Login
Advanced Search

Search for
BioNews

Like the Progress Educational Trust on Facebook



 

Commission demands reform on experimental cell therapies

09 October 2017

By Jennifer Willows

Appeared in BioNews 921

The reputation of stem cell research is being undermined by unscrupulous clinics offering unproven therapies, says a report published last week.

The Lancet Commission on Stem Cells and Regenerative Medicine brought together a number of leading scientists to review progress and consider challenges facing the discipline.

'Regenerative medicine offers transformative potential for the future of patient care. But that potential could be jeopardised by low-quality research and a loss of public trust in stem cell science,' commented The Lancet's editor-in-chief Dr Richard Horton.

In a sense, the field has been a victim of its own hype. 'Excitement about possible treatments for incurable diseases like multiple sclerosis and Parkinson's disease, inflated by media reports, has led desperate patients and families to a proliferating number of poorly regulated clinics peddling untested and potentially ineffective therapies,' the report says.

Stem cell therapies have been shown to be extremely effective in a number of skin and blood disorders, including patients with severe combined immunodeficiency – the former 'bubble babies' born without functioning immune systems – and look promising for other blood disorders such as beta-thalassemia (see BioNews 920). However progress has been significantly slower in other tissues.

Professor Giulio Cosso of the University of Manchester, who lead the commission, explained that in other organs, 'fixing' the cells is not enough.  

'As soon as you move to diseases that affect the muscles, the brain and the heart, you can't remove the diseased tissue. You add your healthy or cured cell to 95 that have not been cured,' he said.

The gap between public expectations and the number of proven treatments has allowed a market to spring up offering unproven treatments, often at high prices.

A well-known example is Davide Vanonni, who despite holding no medical or scientific qualifications offered stem cell treatments for neurological conditions in Italy before being convicted of conspiracy and fraud in 2015 (See BioNews 878).

Last month the FDA announced that it would be taking a tougher stance against US clinics offering unproven stem cell treatments (see BioNews 916). Treatments using only the patient's own cells are not subject to the same level of regulation as drugs under US law if the cells are only 'minimally manipulated' – and similar loopholes exist in many jurisdictions.

But the report argues that 'new therapies expose patients to risks, some of which are difficult to predict even with inbuilt safeguards' and that use in humans needs proper governance.

The commission's recommendations broadly fall into calls for improvement in four areas: science, funding models, governance and public engagement.

SOURCES & REFERENCES
The Guardian | 04 October 2017
 
Manchester University | 05 October 2017
 
The Lancet | 04 October 2017
 

RELATED ARTICLES FROM THE BIONEWS ARCHIVE

20 November 2017 - by Martha Henriques 
The US Food and Drug Administration has announced a fast-track review process for gene therapies and other regenerative medicine treatments...
20 November 2017 - by Dr Patrick Foong 
Stem cell research holds tremendous promise for the treatment of a wide variety of illnesses and conditions, from spinal cord injury to autism. However, much more work is necessary to translate stem cell research into safe and effective therapies...

04 September 2017 - by Rikita Patel 
The US Food and Drug Administration intends to investigate the use of unproven stem cell therapies being offered in the country's clinics...
10 July 2017 - by Lea Goetz 
International experts are calling for global action on unproven and potentially dangerous stem cell therapies and their misleading marketing to the public...
02 May 2017 - by Cathal Farrell 
The ability of stem cells to divide into different mature cell types has ignited the field of regenerative medicine. Stem cells promise to repair and regenerate damaged or diseased tissues without the need for orthodox medical or surgical interventions. However, there is disparity between the expectations held by the general public and some medical professionals versus the reality of the emerging clinical evidence...
21 November 2016 - by Rachel Siden 
Italian prosecutors are investigating whether discredited stem-cell entrepreneur Davide Vannoni is continuing to offer his unproven therapies in eastern Europe...
21 September 2015 - by Paul Waldron 
The Food and Drug Administration must do more to control clinics offering unproven stem cell treatments in the USA, say scientists....

HAVE YOUR SAY
Be the first to have your say.

You need to or  to add comments.

By posting a comment you agree to abide by the BioNews terms and conditions


- click here to enquire about using this story.

Published by the Progress Educational Trust

CROSSING FRONTIERS

Public Conference
London
8 December 2017

Speakers include

Professor Azim Surani

Professor Magdalena Zernicka-Goetz

Professor Robin Lovell-Badge

Sally Cheshire

Professor Guido Pennings

Katherine Littler

Professor Allan Pacey

Dr Sue Avery

Professor Richard Anderson

Dr Elizabeth Garner

Dr Andy Greenfield

Dr Anna Smajdor

Dr Henry Malter

Vivienne Parry

Dr Helen O'Neill

Dr César Palacios-González

Philippa Taylor

Fiona Fox

Sarah Norcross

Sandy Starr


BOOK HERE

Good Fundraising Code

Become a Friend of PET HERE and give the Progress Educational Trust a regular donation